TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All women with singleton or twin pregnancies attending for routine ultrasound examination at 20-25 weeks of gestation with a short cervical length (\<15 mm).~Exclusion Criteria:~* Women with major fetal abnormalities,~* Painful regular uterine contractions, or history of ruptured membranes or cervical cerclage in-situ were excluded from screening.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are receiving continuous renal replacement therapy and are prescribed voriconazole therapy for the treatment or prophylaxis of a fungal infection.~Exclusion Criteria:~* Patients expected to be on CRRT for \< 5 days,~* Patients with Child-Pugh C cirrhosis, and~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Voriconazole (Type: None): Pharmacokinetic Monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis).~* Male or female subjects \>= 18 years of age (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.~* Patients with moderate to severe RA defined as Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 C- Reactive Protein (CRP) \>3.2~* Biologically treatment naïve and initiated adalimumab at baseline visit~* Availability of clinical data of the previous 12 weeks prior to baseline~* Ability to self-complete patient questionnaires~* Subject must be able and willing to provide written informed consent and comply with the requirements of this study protocol.~Exclusion Criteria:~* Patients who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.~* Participation in any RA-related clinical trial at the time of enrolment, at baseline or at any point during the past 24 weeks prior to baseline~* Patients, who in the clinician's view, may not be able to accurately report their QoL or prior resource utilization~* Patients, who in the clinician's view, may not be able to adhere to adalimumab therapy over 24 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females (18-75 years of age)~* At least two cardiovascular disease risk factors~* Must have been following a restrictive diet~* Diagnosis of primary hypercholesterolemia or combined dyslipidemia~Exclusion Criteria:~* Homozygous familial hypercholesterolemia~* Conditions which may cause secondary dyslipidemia~* Uncontrolled diabetes mellitus~* Abnormal pancreatic, liver or renal function~* Abnormal serum creatine kinase (CK) above the pre-specified level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pitavastatin 4 mg QD (Type: EXPERIMENTAL): Pitavastatin 4 mg once daily
- Simvastatin 40 mg QD (Type: ACTIVE_COMPARATOR): Simvastatin 40 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study(Additional) of URC102 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~Exclusion Criteria:~* Participated in other clinical study within past 3 months prior to receiving an IP administration

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- URC102 (Type: ACTIVE_COMPARATOR): URC102

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BIO|MASTER.Ilivia Family / Plexa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Standard indication for ICD or CRT-D therapy according to clinical practice~* De novo implantation or upgrade/exchange (group A only) from existing ICD, CRT-D or pacemaker implant~* Patient is able to understand the nature of the clinical investigation and provides written informed consent~* Patient is able and willing to complete all routine study visits at the investigational site~* Patient accepts Home Monitoring concept~* Age ≥ 18 years~Exclusion Criteria:~* Contraindication to ICD or CRT-D therapy, respectively~* For CRT-D patients in group A only: physician not willing to activate MultiPole Pacing in the patient~* Cardiac surgical procedure planned within 6 months after implantation (including also interventional procedures like ablation, valve replacement etc.). Procedures to occur during or prior to implantation are not exclusionary.~* Expected to receive heart transplant or ventricular assist device within 6 months~* Life expectancy less than 6 months~* Participation in any other interventional clinical investigation~* Pregnant or breastfeeding at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ilivia ICD Family (Type: OTHER): Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
- Plexa ICD lead (Type: OTHER): Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
- Ilivia ICD and Plexa lead (Type: OTHER): Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Classic Hodgkin Lymphoma (cHL), relapsed or refractory~* Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants \> 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.~* One prior anti-cancer therapy that did not work~Exclusion Criteria:~* Active, known, or suspected autoimmune disease or infection~* Active cerebral/meningeal disease related to the underlying malignancy~* More than one line of anti-cancer therapy or no treatment at all~* Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant~* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Nivolumab + brentuximab vedotin (Type: EXPERIMENTAL): None
- brentuximab vedotin + bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (1) at least 18 years old;~* (2) free of any psychiatric diagnoses or medication (besides a substance use disorder to alcohol, tobacco, or cannabis);~* (3) in the past month, at least 4 episode of heavy episodic drinking; at least 3 occasion of cannabis use; and daily cigarette use for at least the past month;~* (4) normal or corrected-to-normal vision;~* (5) written informed consent;~* (6) no previous meditation or neurofeedback (NF) experiences.~Exclusion Criteria:~* (1) any psychiatric diagnoses other than a substance use disorder;~* (2) medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females);~* (3) excluding cannabis, evidence of recent (past month) illicit drug use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Integrative Body Mind Training (IBMT) (Type: EXPERIMENTAL): mindfulness
- Relaxation Training (RT) (Type: ACTIVE_COMPARATOR): relaxation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Following verbal and written information about the trial, subject must provide informed consent documented by signing the Informed Consent Form (ICF) prior to any trial related procedures~2. Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm² treatment area on the face or scalp~Exclusion Criteria:~1. Location of the selected treatment area:~* on the periorbital skin~* on the perioral skin/around the nostrils~* within 5 cm of an incompletely healed wound~* within 10 cm of a suspected BCC or SCC or other neoplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: ACTIVE_COMPARATOR): Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
- Treatment Group B (Type: ACTIVE_COMPARATOR): Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2009; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted~* Current or former cigarette smokers~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit~* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1~* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness~* History or presence of asthma verified from medical records~* Chronic use of oxygen therapy greater than or equal to 15 hours per day~* Patient with uncontrolled infection due to HIV and/or active hepatitis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics~* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 12 weeks of treatment
- 2 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 12 weeks of treatment
- 3 (Type: PLACEBO_COMPARATOR): Inhaled placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of at least 18 years of age~* Histologically proven Bladder cancer~* Locally advanced or metastatic disease (stage IV)~* Functional status (ECOG / OMS) ≤ 2~* Relapse after first-line chemotherapy~* Measurable lesions (RECIST criteria)~* Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.~* Biological levels :~* Neutrophil count \>1,5.109/L.~* Platelets \>100.109/L~* Total serum bilirubin \< 1.5 × ULN~* Clearance of créatinine 40 ml/mm~* If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 × ULN~* With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<5 × ULN~* Signed informed consent~* Both women and men must agree to use a medically acceptable method of contraception throughout the study. Women of childbearing potential must have a negative serum pregnancy test of or less than 7 days before the first perfusion of study.~* France only : Patients affiliated to a social security program~Exclusion Criteria:~* Presence of metastatic brain or meningeal tumors on selection scanner, weither symptomatic or asymptomatic~* Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion~* Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or polysorbate 80 or to their excipients~* Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma curatively treated) or incidental (≤ pT2) prostate cancer found on a radical cystoprostatectomy material~* The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on the 30th day ( or at least 7 halves-lives, according to the shortest duration) before the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be purposely excluded.~* Auto-immune pathology, psychiatric or neurological disorder~* Any unstable medical condition~* Unstable cardiac disease~* Severe renal failure~* Unstable diabetes~* Pregnancy~* Patient enrolled in another therapeutic clinical trial~* Patient unable to follow and comply with the study procedures because of any geographical, social or medical condition~* Patient partially or totally deprived of his civil rights

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 80 years (inclusive);~* proven or suspected infection;~* meeting 2 of 4 of the systemic inflammatory response syndrome (SIRS) criteria;~* septic shock or one or more acute organ failures in the preceding 12 hours;~* written informed consent obtained.~Exclusion Criteria:~* Pregnant or lactating women;~* known HIV seropositive patients;~* patients receiving immunosuppressive therapy or chronically using high doses of glucocorticosteroids (defined as \> 1 mg/kg/day) equivalent to prednisone 1 mg/kg/day;~* patients expected to have rapidly fatal disease within 24 h;~* known confirmed gram-positive sepsis;~* known confirmed fungal sepsis;~* chronic renal failure requiring haemodialysis or peritoneal dialysis;~* acute pancreatitis with no established source of infection;~* patients not expected to survive for 28 days due to other medical conditions such as end-stage neoplasm or other diseases;~* participation in another investigational study within 90 days prior to start of the study which might interfere with this study;~* previous administration of AP;~* known allergy for cow milk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BIAP
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Saxagliptin on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus defined by fasting glucose ≥126 mg/dl or HbA1c ≥6.5% or on blood glucose lowering medication~* Age of 18 - 75 years~* Male and Female patients are eligible. Females of child bearing potential or within two years of the menopause are only eligible if pregnancy test at the screening visit is negative and they use adequate contraceptive precautions during the trial.~* The patient must demonstrate that she/he is able and willing to perform blood glucose measurements as necessary for Home Blood Glucose Monitoring by herself/himself after it was demonstrated to her/him.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Patients with more than on one blood glucose lowering medication or on insulin therapy~* Last measured HbA1c \> 11%~* Blood pressure levels ≥180/110 mmHg~* Body mass index \>50 kg/m²~* Triglyceride levels \>1000 mg/dl~* HDL-cholesterol levels \<25 mg/dl~* Estimated creatinine clearance \< 50 ml/min/1.73m²~* Macroalbuminuria defined by urinary albumine-to-creatinine ratio \> 300 mg/g~* Known liver function test \>3 times upper limit of normal~* Pregnant or breast-feeding patients~* Current or previous (within 6 months) treatment with an incretin-based therapy such as DPP 4 inhibitors and/or GLP-1 mimetics~* Any patient currently receiving chronic (\>30 consecutive days) treatment with an oral corticosteroid~* Acute cardiovascular event (including myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, heart failure, stroke, TIA. PRIND, intracerebral bleeding) \<6 months prior to screening visit (visit 1)~* Diabetic retinopathy~* History of epilepsia or history of seizures~* Patients being treated for severe auto immune disease e.g. lupus~* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and BMS or representative staff and/or staff at the study site)~* Previous randomisation in the present study~* Participation in another clinical study within 30 days prior to visit 1~* Individuals at risk for poor protocol or medication compliance~* Subject who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Saxagliptin (Type: ACTIVE_COMPARATOR): saxagliptin 5 mg/day during 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete